At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma
In Brief
A Phase 2 clinical trial evaluating Ipilimumab, Laboratory Biomarker Analysis, and 2 other interventions for Locally Advanced Bone Sarcoma and 20 related conditions. Completed, enrolled 164 participants across 651 sites.
Detailed Summary
This randomized phase II trial studies how well nivolumab with or without ipilimumab works in treating patients with sarcoma that has spread from the primary site to other parts of the body (metastatic) or cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether nivolumab works better with or without ipilimumab in treating patients with metastatic or unresectable sarcoma.
Study Details
Timeline
Interventions
Given IV
Correlative studies
Given IV
Ancillary studies